MedTrace Logo

Effectiveness and Safety of Omalizumab in Children With Allergic Asthma.

NCT05424523 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-07-05

No results posted yet for this study

Summary

The study was the non-interventional, retrospective study aimed to assess the effectiveness and safety of omalizumab in children with allergic asthma in China, and described patient profiles and treatment patterns of omalizumab in real-world practice.

Conditions

  • Allergic Asthma

Interventions

DRUG

Omalizumab

Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
6 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-25
Primary Completion
2021-06-28
Completion
2021-06-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05424523 on ClinicalTrials.gov